A Terrifying Superbug Just Showed Up on a US Farm for the First Time

The bacteria found in a hog operation is resistant even to some of our most powerful antibiotics.

<a href="http://www.istockphoto.com/photo/pig-farm-gm482968667-37313908?st=_p_hog%20farm">Suljo</a>/iStock

Fight disinformation: Sign up for the free Mother Jones Daily newsletter and follow the news that matters.


More than 70 percent of the antibiotics consumed in the United States go to livestock farms, one of the main triggers driving a rising crisis of antibiotic resistance in human medicine.

On Tuesday, researchers from Ohio State University published an alarming finding in a peer-reviewed journal: On a US hog farm, they found bacteria that can withstand a crucial family of antibiotics. Carbapenems, as they are known, are a “last line of defense” against bacterial pathogens that can resist other antibiotics, the paper notes. Worse still, the gene that allowed the bacteria to resist carbapenems turned up in a plasmid—small chunks of DNA found in bacterial cells. Plasmid-carried genes bounce easily from one bacterial strain to another, meaning that carbapenem resistance is highly mobilemaking it more likely to find its way into bacterial pathogens that infect people.

“Infections with these germs are very difficult to treat, and can be deadly—the death rate from patients with CRE bloodstream infections is up to 50 percent.”

If this news sounds depressingly familiar, it’s because something very similar happened with another last-ditch antibiotic, colostin. About a year ago, Chinese researchers alarmed global public health authorities when they found a “plasmid-mediated” strain of colistin-resistant E. coli on a Chinese hog farm. As predicted, it quickly went global, and it turned up in the United States in a patient in May, as well as in a pig intestine identified by US Department of Agriculture researchers. In September, Rutgers and Columbia University researchers found a strain of E. coli with plasmid-carried resistance to colostin and carbapenems. The new Ohio State study marks the first time plasmid-borne carbapenem resistance has been found on a US farm, though it has turned up in livestock operations in Asia and Europe, the researchers write.

To see whether carbapenem resistance is taking hold on US hog farms, the researchers settled on a 1,500-sow confined operation that follows “typical US production practices,” which include giving newborn pigs a dose of an antibiotic called ceftiofur at birth, with the males getting a second dose when they’re castrated at six days. Interestingly, carbapenems are banned from use in US farms. But ceftiofur is a member of the cephalosporin family of antibiotics, which kills bacteria in a similar way to carbapenems, and the authors speculate that those ceftiofur doses “may provide significant selection pressure” for the emergence of carbapenem resistance. They found it in swabs taken from the the surfaces of the farrowing and nursery pens.

Interestingly, the pigs don’t get ceftiofur after those initial doses at birth, except to treat sickness. And at later stages of the pig-raising process, such as the finishing barns where pigs are fattened to slaughter weight, no carbapenem-resistant bacteria turned up. That’s likely because the absence of ceftiofur “likely removed antimicrobial selection pressure” for the resistant gene, causing it to lose its niche. That absence of carbapenem-resistant bacteria in the late-stage pigs is good news—it means the superbug is “unlikely to have entered the food supply through contamination of fresh pork products.”

But given how quickly the gene can jump from one bacterial strain to another, the study identified a ticking time bomb. Cephalosporins, the class of antibiotics that may have triggered the carbapenem-resistant bacteria  on this particular farm, aren’t administered nearly as much as other antibiotics on US farms, but alarmingly their use jumped 57 percent between 2009 and 2014, according to the latest Food and Drug Administration numbers. And the Ohio State study settled on one typical US hog operation. Who knows what’s going on with the 21,000-plus others.

Over on the Natural Resources Defense Council blog, antibiotic-resistance expert David Wallinga notes that the bacteria that turned up in the Ohio State study is carbapenem-resistant Enterobacteriaceae, “one of the nastier superbugs.” He continues:

Infections with these germs are very difficult to treat, and can be deadly—the death rate from patients with CRE bloodstream infections is up to 50 percent. The CDC says these bacteria already cause 9,300 infections, and 600 deaths each year. To date, CRE infections occur mostly among patients in hospitals and nursing homes; people on breathing machines, or with tubing inserted into their veins or bladders are at higher risk, as are people taking long courses of certain antibiotics. But newer, more resistant kinds of CRE seem to be causing  more problems outside hospitals, in communities and among healthier people.

Way back in 2012, the Obama administration introduced a new set of guidelines—that will finally go into full effect on January 1—designed to preserve antibiotics as a bulwark against dangerous infections by curbing their use on farms. As I show here, meat farms use about three times as much of these vital drugs as does human medicine. Yet the Obama guidelines are both voluntary and contain a huge loophole, which I tease out here. And now, even as terrifying superbugs continue appearing in the United States, we have a new president whose agriculture advisers have expressed nothing but hostility toward regulating food production.

WE CAME UP SHORT.

We just wrapped up a shorter-than-normal, urgent-as-ever fundraising drive and we came up about $45,000 short of our $300,000 goal.

That means we're going to have upwards of $350,000, maybe more, to raise in online donations between now and June 30, when our fiscal year ends and we have to get to break-even. And even though there's zero cushion to miss the mark, we won't be all that in your face about our fundraising again until June.

So we urgently need this specific ask, what you're reading right now, to start bringing in more donations than it ever has. The reality, for these next few months and next few years, is that we have to start finding ways to grow our online supporter base in a big way—and we're optimistic we can keep making real headway by being real with you about this.

Because the bottom line: Corporations and powerful people with deep pockets will never sustain the type of journalism Mother Jones exists to do. The only investors who won’t let independent, investigative journalism down are the people who actually care about its future—you.

And we hope you might consider pitching in before moving on to whatever it is you're about to do next. We really need to see if we'll be able to raise more with this real estate on a daily basis than we have been, so we're hoping to see a promising start.

payment methods

WE CAME UP SHORT.

We just wrapped up a shorter-than-normal, urgent-as-ever fundraising drive and we came up about $45,000 short of our $300,000 goal.

That means we're going to have upwards of $350,000, maybe more, to raise in online donations between now and June 30, when our fiscal year ends and we have to get to break-even. And even though there's zero cushion to miss the mark, we won't be all that in your face about our fundraising again until June.

So we urgently need this specific ask, what you're reading right now, to start bringing in more donations than it ever has. The reality, for these next few months and next few years, is that we have to start finding ways to grow our online supporter base in a big way—and we're optimistic we can keep making real headway by being real with you about this.

Because the bottom line: Corporations and powerful people with deep pockets will never sustain the type of journalism Mother Jones exists to do. The only investors who won’t let independent, investigative journalism down are the people who actually care about its future—you.

And we hope you might consider pitching in before moving on to whatever it is you're about to do next. We really need to see if we'll be able to raise more with this real estate on a daily basis than we have been, so we're hoping to see a promising start.

payment methods

We Recommend

Latest

Sign up for our free newsletter

Subscribe to the Mother Jones Daily to have our top stories delivered directly to your inbox.

Get our award-winning magazine

Save big on a full year of investigations, ideas, and insights.

Subscribe

Support our journalism

Help Mother Jones' reporters dig deep with a tax-deductible donation.

Donate